Hematide

PALO ALTO, Calif., Dec 08, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Chris Dammann, vice president, Business Development, will participate in a panel discussion at the RBC Capital Markets Healthcare Conference on Wednesday, December 10, 2008, at 4:30 p.m. EST in New York. A live webcast of th...

PALO ALTO, Calif., Nov 20, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide(TM), has completed another review and has informed the company that the cumulative safety data generated thus far f...

PALO ALTO, Calif., Nov 17, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the remaining Phase 3 clinical trial of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 2...

PALO ALTO, Calif., Nov 13, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that management will present at the Lazard Capital Markets 5th Annual Healthcare Conference on Wednesday, November 19, 2008, at 11:30 a.m. EST at The St. Regis in New York. A live webcast of the presentation will be available on the investors section ...

PALO ALTO, Calif., Nov 13, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that the company will host a live webcast of its analyst and investor event on Thursday, November 20, 2008, at 9:00 a.m. EST. The event will feature two experts: Robert Geronemus, M.D., a Hematide clinical investigator who will provide his perspective...

PALO ALTO, Calif., Nov 13, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dial...

PHILADELPHIA, Nov 06, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced at the American Society of Nephrology Renal Week 2008 in Philadelphia positive results from a long-term safety and effectiveness study of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal fai...

PALO ALTO, Calif., Nov 06, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2008. The net loss for the third quarter of 2008 was $26.2 million compared to a net loss of $12.7 million for the third quarter of 2007. Affymax recognized revenue for the quarter ended Septe...

PALO ALTO, Calif., Nov 03, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the second of four Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 2 (Phase 3 Evaluation of Hema...

PALO ALTO, Calif., Oct 23, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that management will present at the following investor conferences. Chris Dammann, vice president of Business Development, will present at the 7th Annual BIO Investor Forum Palace Hotel, San Francisco Thursday, October 30, 2008 11:30 a.m. PT Arle...

PALO ALTO, Calif., Sep 17, 2008 (BUSINESS WIRE) -- Affymax, Inc. (NASDAQ: AFFY) today announced that management will present at the 2008 UBS Global Life Sciences Conference on Thursday, September 25, 2008, at 1:00 p.m. ET at the Grand Hyatt New York. A live webcast of the presentation will be available on the investors section of the Company's ...

PALO ALTO, Calif., Aug 28, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Affymax management will host a conference call and webcast at 5:00 p.m. Eastern Time today. The call will discuss the joint Affymax and Takeda decision to focus all development efforts for Hematide(TM) on the treatment of anemia associated with chron...

OSAKA, Japan & PALO ALTO, Calif., Aug 28, 2008 (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502) and Affymax, Inc. (Nasdaq:AFFY) today announced their agreement to suspend co-development of Hematide(TM) to treat chemotherapy-induced anemia and to focus all development efforts for Hematide(TM) on the treatment of chronic kidney d...

PALO ALTO, Calif., Aug 28, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the Company's participation at the following investor conferences during the month of September. Thomas Weisel Partners Healthcare Conference 2008 Four Seasons Hotel, Boston September 3 8:35 a.m. Eastern Time BioCentury Newsmakers in the Biotech I...

PALO ALTO, Calif., Aug 18, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the second quarter ended June 30, 2008. The net loss for the second quarter of 2008 was $18.9 million compared to a net loss of $9.2 million for the second quarter of 2007. Affymax recognized revenue for the quarter ended June 30,...

PALO ALTO, Calif., Aug 07, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide(TM), has completed its first review of the data and informed the company that the cumulative safety data generated thus far from the EMERAL...

PALO ALTO, Calif., Jul 28, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the Company's participation at the following investor conferences in August. Arlene Morris, president and chief executive officer, will present at BMO Capital Markets Focus on Healthcare 2008 Investor Conference Millennium Broadway Hotel, New Yor...

PALO ALTO, Calif., Jul 09, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the first of four Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 1 (Phase 3 Evaluation of Hemat...

PALO ALTO, Calif., Jun 30, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has begun in a Phase 2 clinical trial of Hematide(TM) to correct anemia in patients with chronic renal failure (CRF) who are undergoing dialysis and are not actively being treated with an erythropoiesis stimulating agent (ESA). The trial i...

PALO ALTO, Calif., Jun 04, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the promotions of Robert F. Venteicher, Ph.D. to senior vice president, Technical Operations and Grace U. Shin, J.D., to general counsel. "I am pleased to recognize the significant and important contributions that both Bob and Grace have made in the g...